Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Stock data | 2024 | Change |
---|---|---|
Price | $8.45 | N/A |
Market Cap | $242.22M | N/A |
Shares Outstanding | 28.67M | N/A |
Employees | 137.00 | N/A |